Sweeny Nicole 4
4 · KalVista Pharmaceuticals, Inc. · Filed Aug 25, 2025
Insider Transaction Report
Form 4
Sweeny Nicole
Chief Commercial Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-08-21−6,250→ 87,500 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2025-08-21+6,250→ 30,635 total - Sale
Common Stock
2025-08-22$13.22/sh−1,864$24,647→ 28,771 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.